sofosbuvir
Term · Oncology and biomedicine · MLC-T-ONC-016815
An orally available nucleotide prodrug and a hepatitis C virus (HCV) NS5B polymerase inhibitor with potential HCV inhibiting activity. Upon oral administration, sofosbuvir is metabolized to 2'-deoxy-2'-alpha-fluoro-beta-C-methyluridine-5'-monophosphate, which is then converted into the active triphosphate nucleotide that inhibits the NS5B polymerase, thereby preventing viral replication. The HCV NS5B protein, an RNA-dependent RNA polymerase, is essential for the replication of the viral HCV RNA genome.
| Identifier | MLC-T-ONC-016815 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | nucleotide NS5B inhibitor GS-7977 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-016815",
"term": "sofosbuvir",
"field": "Oncology and biomedicine",
"definition": "An orally available nucleotide prodrug and a hepatitis C virus (HCV) NS5B polymerase inhibitor with potential HCV inhibiting activity. Upon oral administration, sofosbuvir is metabolized to 2'-deoxy-2'-alpha-fluoro-beta-C-methyluridine-5'-monophosphate, which is then converted into the active triphosphate nucleotide that inhibits the NS5B polymerase, thereby preventing viral replication. The HCV NS5B protein, an RNA-dependent RNA polymerase, is essential for the replication of the viral HCV RNA genome.",
"synonyms": [
"nucleotide NS5B inhibitor GS-7977"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/sofosbuvir/"
}
Record 15,160 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.